Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying adult patients with Neurofibromatosis type 1 NF1 in Russia to evaluate clinical and patient-reported outcomes in routine care settings. This observational, open-label, single-arm, multi-center cohort study focuses on adults diagnosed with NF1 and associated plexiform neurofibromas PN. Participants are adults aged 18 years or older with confirmed NF1 and PN diagnosis verified by clinical assessment, ultrasound imaging, MRI, or biopsy. The study includes patients with existing PN-associated symptoms who are either newly diagnosed or have PN without prior MEK-inhibitor therapy. No investigational drugs are given, as this is a non-interventional study observing routine care. During the study, participants provide data at their initial visit, including demographics, clinical history, PN characteristics, comorbidities, disability degree, and prior examinations. Researchers collect information on hospitalizations and disease progression over time. The primary outcomes include age at inclusion and diagnosis, body measurements, symptom duration, and disability changes. Participants are followed according to routine care until study completion in 2028.
Actively Recruiting
Researchers are evaluating clinical outcomes for patients who begin inclisiran treatment within about two weeks after experiencing a heart attack STEMI or non-STEMI. This observational study focuses on patients in Russia and aims to understand the effects of inclisiran on lipid profiles, safety, atherosclerotic plaque status using carotid ultrasound, and the rates of hospitalizations and intensive follow-up over a 12-month period. Participants receive their first inclisiran injection approximately 14 days after their heart attack. The study observes changes in lipid levels at baseline, 3, 9, and 12 months, as well as plaque progression or regression over the year. Researchers also monitor adverse events, therapy discontinuation, hospital readmissions, emergency care visits, and the timing of dispensary observation. During the 12 months of participation, patients undergo lipid profile testing, carotid ultrasound scans, and safety evaluations at specified intervals. The main measure is the number of patients experiencing atherosclerotic cardiovascular disease events within a year after starting inclisiran in addition to their usual therapy. Secondary assessments include LDL cholesterol levels, plaque changes, adverse events, rehospitalizations, and use of emergency services, all tracked to evaluate the therapys impact and safety in real-world settings.